D. Stroyakovskiy

发表

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

P. Ascierto, J. Larkin, A. Ribas, 2014, The New England journal of medicine.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

J. Utikal, A. Hauschild, D. Schadendorf, 2014, The New England journal of medicine.

Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

Federico Cappuzzo, M. Socinski, F. Cappuzzo, 2018, The New England journal of medicine.

IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.

M. Socinski, F. Cappuzzo, D. Moro-Sibilot, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).

W. Symmans, V. Valero, Chiun-Sheng Huang, 2016 .

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

L. Demidov, F. Moiseenko, N. Zhukova, 2021, Cancers.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

M. Beckmann, W. Symmans, V. Valero, 2018, The Lancet. Oncology.

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.

T. Ciuleanu, B. Alekseev, S. Pal, 2022, European urology.

Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia

D. Stroyakovskiy, S. Gamayunov, A. Zhabina, 2019 .

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

B. Xu, X. Pivot, J. Pierga, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

J. Ahn, B. Melichar, X. Pivot, 2019, JAMA oncology.

Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial

D. Stroyakovskiy, S. Gamayunov, A. Zhabina, 2020, Meditsinskiy sovet = Medical Council.

Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2016 .

25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study

P. Ascierto, J. Larkin, A. Ribas, 2015 .

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

P. Fasching, W. Symmans, V. Valero, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, The New England journal of medicine.

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.

Sung-Bae Kim, Shou‐Tung Chen, J. Ahn, 2016, European journal of cancer.

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab

D. Stroyakovskiy, M. Matrosova, R. Nagarkar, 2021, BMC cancer.

Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON

F. Moiseenko, D. Stroyakovskiy, A. Tryakin, 2021, Journal of Modern Oncology.

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

E. Van Cutsem, C. Borg, H. Wasan, 2022, British Journal of Cancer.

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

M. Socinski, F. Cappuzzo, D. Moro-Sibilot, 2018 .

Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients withBRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial

P. Ascierto, H. Gogas, P. Rutkowski, 2020 .

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia.

A. Kudryavtseva, S. Tjulandin, M. Filipenko, 2019, Journal of Clinical Oncology.

T. Ciuleanu, B. Alekseev, S. Pal, 2022, The oncologist.

P. Ascierto, J. Larkin, A. Ribas, 2018, British Journal of Cancer.

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

E. Zueva, L. Bolotina, D. Stroyakovskiy, 2021 .

Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).

J. Ahn, B. Melichar, X. Pivot, 2015 .

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.

R. Motzer, T. Powles, B. Mellado, 2021, JAMA oncology.

134PD Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)

M. Socinski, D. Moro-Sibilot, F. Barlesi, 2018 .

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.

M. Socinski, F. Cappuzzo, T. Mok, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL.

D. Schadendorf, M. Casey, C. Garbe, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.

B. Melichar, X. Pivot, C. Jackisch, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)

N. Bogdanova, J. Pierga, I. Smith, 2008 .

Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

K. Flaherty, A. Arance, H. Gogas, 2019, Annals of Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Matthew Wongchenko, Paolo A Ascierto, Antoni Ribas, 2016, The Lancet. Oncology.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

Abstract OT2-01-12: ENCORE 602: A randomized, placebo-controlled, double-blind, multicenter phase 2 study (with a phase 1b lead-in) of atezolizumab with or without entinostat in patients with advanced triple negative breast cancer (aTNBC)

A. Forero, D. Slamon, D. Stroyakovskiy, 2017 .

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study.

K. Flaherty, J. Larkin, H. Gogas, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

J. Bono, C. Sternberg, M. Borre, 2021, The Lancet.

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.

P. Ascierto, L. Demidov, R. Gutzmer, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

P. Ascierto, H. Gogas, P. Rutkowski, 2020, The Lancet.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European journal of cancer.

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, The Lancet. Oncology.

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

P. Ascierto, A. Ribas, C. Garbe, 2021, Clinical Cancer Research.

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

Y. Hotko, K. Syrigos, M. Gumus, 2021, BioDrugs.

Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study.

E. Van Cutsem, C. Punt, V. Moiseenko, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

M. Socinski, F. Cappuzzo, T. Mok, 2019, The Lancet. Respiratory medicine.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The Lancet. Oncology.

results from a randomised, double-blind, phase 3 trial

P. Ascierto, J. Larkin, A. Ribas, 2016 .

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial.

M. Socinski, F. Cappuzzo, V. Graupner, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.

P. Ascierto, J. Larkin, A. Ribas, 2018 .

Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC).

J. Pierga, I. Smith, C. Thomssen, 2009 .

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

A. Hauschild, S. Puig, R. Fisher, 2021, European journal of cancer.

Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, Journal of Clinical Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, Journal of Clinical Oncology.

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.

P. Ascierto, J. Larkin, A. Ribas, 2015 .

ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC

N. Pavlakis, A. Shaw, T. Mok, 2018, Pneumologie.

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

M. Socinski, F. Cappuzzo, V. Graupner, 2018, Journal of Clinical Oncology.

Role of surgical treatment in patients with EGFR mutation-positive locally advanced and disseminated non-small-cell lung cancer

D. Stroyakovskiy, P. Kononets, M. Popov, 2021, Onkologiya. Zhurnal imeni P.A.Gertsena.

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

P. Ascierto, J. Larkin, A. Ribas, 2015, Journal of Translational Medicine.

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

J. Stebbing, D. Stroyakovskiy, A. Eniu, 2019, Cancer Chemotherapy and Pharmacology.

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

E. Van Cutsem, J. Tabernero, M. Fakih, 2023, Journal of Clinical Oncology.

Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC.

S. Tjulandin, D. Stroyakovskiy, G. Adamchuk, 2015 .

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

S. Loi, G. Hortobagyi, A. Bardia, 2023, Therapeutic advances in medical oncology.

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.

C. Punt, V. Moiseenko, C. Borg, 2021 .

OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC

M. Socinski, R. Soo, M. Mccleland, 2019, Journal of Thoracic Oncology.

Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.

E. Van Cutsem, J. Tabernero, M. Fakih, 2023, The New England journal of medicine.

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

A. Hauschild, D. Schadendorf, K. Flaherty, 2020 .

Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).

P. Ascierto, J. Larkin, A. Ribas, 2015 .

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

J. Utikal, A. Hauschild, D. Schadendorf, 2019 .

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.

F. Meric-Bernstam, B. Melichar, K. Jung, 2023, Journal of Clinical Oncology.

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

A. Gasbarrini, W. Li, H. Harputluoglu, 2023, The Lancet.

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.

M. Socinski, T. Mok, D. Moro-Sibilot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.

S. Loi, G. Hortobagyi, A. Bardia, 2023, Journal of Clinical Oncology.

P. Ascierto, J. Larkin, A. Ribas, 2015, Journal of Translational Medicine.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European Journal of Cancer.

1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations

M. Socinski, T. Mok, F. Barlesi, 2020 .

Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups

M. Socinski, F. Cappuzzo, T. Mok, 2020 .

Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma.

P. Ascierto, H. Gogas, P. Rutkowski, 2020, Journal of Clinical Oncology.

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

F. Meric-Bernstam, B. Melichar, A. Oaknin, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis.

V. Moiseenko, R. Glynne-Jones, N. Amellal, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study

D. Stroyakovskiy, K. Grechukhina, N. Fadeeva, 2024, Journal of Modern Oncology.

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

G. Hortobagyi, D. Yardley, M. Ruíz-Borrego, 2024, The New England journal of medicine.

Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study

D. Stroyakovskiy, S. Protsenko, S. Odintsova, 2023, Journal of Modern Oncology.

Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).

T. Ciuleanu, B. Alekseev, S. Pal, 2021 .